Quest Diagnostics Incorporated (DGX)

Investment Committee Summary

Investment Thesis

At $233 (13 October 2026) Quest trades within a whisker of its 52-week high and on 21x forward earnings, a clear premium to laboratory peers. The market is paying a quality premium for a low-single-digit organic grower, implying confidence that advanced-diagnostics mix and bolt-on acquisitions compound earnings without reimbursement interruption. The engine is less generous. The probability-weighted value of $201 and the twelve-month target of $198 both sit beneath spot, and the discounted-cash-flow anchors sit far below the market price, so the equity is carried by its multiple rather than by discounted cash flow. The triangulated fair value of $159 leaves a gap of -32% to spot, and the shares are trading rich to that anchor. Margin is the dominant variance driver on a business earning an operating margin of 14% (reported GAAP, TTM to Jun 2026), which leaves limited room for error, and Monte Carlo places well under half of outcomes above the current price. SELL follows, with a fatter left tail than right and net debt of ~$6.6B funding acquisitions rather than defence. The single most damaging risk is a Medicare fee-schedule cut arriving alongside payer-driven in-house testing, compressing earnings and the multiple together.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($233) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural bear does not require a recession; it requires payers to act in their own interest. Medicare fee-schedule cuts have precedent under PAMA, and commercial insurers are steering volume toward narrow laboratory networks just as large health systems rebuild in-house testing to capture the margin themselves. Quest's operating margin of 14% (reported GAAP, TTM to Jun 2026) is the arbitrage being competed away. In that world organic volumes stagnate, revenue per requisition falls, and the forward multiple, priced for a quality compounder, de-rates toward what a structurally pressured processor earns. The scenario mathematics land below the 52-week low on the largest weight in the downside branch. Debt-funded acquisitions, with net debt of ~$6.6B already outstanding, would accelerate rather than cushion the fall, because a roll-up whose organic base is shrinking must keep buying merely to stand still.

Key Debate

Gross Margin explains 55% of Monte Carlo outcome variance — the single variable that decides which side is right.

What the Market Is Pricing In

At the current price, the market pays 20.8× consensus forward EPS, vs the house DCF terminal 15.0×, and a peer median 14.5×. The house DCF sits 53% below spot, so the market is pricing in more than the house case — roughly 3.9pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Reimbursement / In-House Testing' downside ($89.30) to a 'Bull — Re-Rate' bull case ($361); the probability-weighted blend (PWEV $201) is -14% versus spot.

SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (1.5% of shares, on SBC ≈ 1% of revenue), trimming the gross PWEV of $204 to $201 (-1.5%). SBC is charged once, as dilution — never also deducted from FCF.

Scenario rationale — the driver path behind every target:

• Structural — Reimbursement / In-House Testing (20%, $89.30). Structural impairment — reimbursement / insourcing: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Volume Recession (17%, $153). Cyclical downturn — outsourced service volume + reimbursement per unit + mix + tuck-in M&A weakens for 1–2 years before normalising.
• Base — Volume + Acquisitions (35%, $212). Mid-cycle — normalised outsourced service volume + reimbursement per unit + mix + tuck-in M&A; disciplined capital allocation; steady returns.
• Growth — Advanced-Diagnostics / M&A (20%, $287). Upside — mix upgrade + M&A lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $361). Upside tail — sustained tight conditions or a structural re-rate on mix upgrade + M&A.

Valuation Triangulation

Four weighted anchors — an intrinsic dcf, a scenario-weighted pwev, a monte carlo median (student-t + regime switching) and a peer p/e re-rate — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat four numbers as four independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts is not computed, so 15% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way. The company-lever row in the Sensitivity section is an illustrative EBIT × multiple value, not a sum-of-parts anchor.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $179 and 29% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (55% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — explicit-period cash flows with an exit-multiple terminal

A 5-year cash-flow path discounted at a WACC of 8.5%, plus a terminal value of final-year FCF × 15.0x — a terminal multiple equal to 0.85 × the base multiple that the Monte Carlo and the scenario tree also use → $110. The terminal value is 73% of enterprise value, so this anchor moves with the multiple assumption. The heaviest anchor in this blend (36%); because its terminal is a market multiple, it is not independent of the multiple-driven anchors.

Peer benchmarking — relative value

Against its 4 peers in the same GICS sub-industry, re-rating to their median forward multiple (P/E 14.5x) implies $162. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 13% so market sentiment does not set the fair value.

Across all anchors the spread is 86% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × model op-margin Δ (Δ applied to the DCF's house margin path)

Tornado — DCF/share swing by driver (widest first)

Company lever — value at the base multiple vs Diagnostics & Outsourced Health Services multiple (base 19.0x)

Illustrative: segment EBIT × multiple, plus net cash, over basic shares — it does not enter the triangulated fair value.

Peer Quality & Weighting

Quality-weighted forward P/E: 13.2× (simple median 14.5×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $171–$249, centre $206 (-11% vs spot); spot sits at the 79th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio is (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Reimbursement / In-House Testing' target ÷ price). 'Structural — Reimbursement / In-House Testing' ($89.30, probability 20%) is the lowest-target scenario in the tree, taken gross of SBC dilution. With a leg missing the ratio is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $361.

Company Overview & Business Model

Quest Diagnostics Incorporated — HEALTHCARE · DIAGNOSTICS & RESEARCH. Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil.

Company description as supplied by Alpha Vantage; not checked against the company's filings.

How it makes money.

† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.

Reported operating margin (GAAP): 14.5% for the fiscal year ended 2025-12-31; 14.1% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Edge. Narrow moat. Authored moat rationale withheld pending re-authoring.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

For comparison, the company's reported GAAP operating margin was 14.5% for the fiscal year ended 2025-12-31; 14.1% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 180% — cash-backed.

Competitive Moat

Moat sources:

• Scale and logistics density: national specimen-transport and lab network hard to replicate
• Health-plan in-network contracts and preferred-lab agreements (e.g., UnitedHealthcare) driving volume
• Physician-office and EHR connectivity creating ordering-workflow stickiness
• Reimbursement (PAMA/CMS) and hospital in-sourcing structurally cap pricing power (moat limiter)

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.28 vs analyst floor +0.00 → delta +0.28 (n=23 mgmt / 14 Q&A; 23rd pctile across the S&P book, z -0.8).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1295 articles): avg ticker sentiment +0.21 (bullish 28% / bearish 2%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-22 (~10d) — Quarterly earnings — est. EPS $2.85 (AV EARNINGS_CALENDAR)
• 2026-11-15 (~34d) — PAMA / CMS Clinical Lab Fee Schedule reimbursement-rate decision for the coming year (authored)
• 2027-01-30 (~110d) — FY2026 results and FY2027 organic-growth / M&A-contribution guidance (authored)

Forecast Track Record

• EPS surprise: beat 100% of the last 8 quarters; average surprise +4.0%.

Catalyst Timeline

6 catalysts in the next 90 days (of 14 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Scenario-macro rows withheld pending re-authoring: 1 carrying another cluster's vocabulary or a frozen figure — recorded in the narrative quarantine ledger.

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 1 bearish / 1 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth (ex-M&A), year on year < 0.01 (2 consecutive prints). Base case assumes roughly 3.0 pct organic growth from volumes and advanced-test mix. Two prints below 1.0 pct means volume or steerage pressure is real, shifting weight toward the Volume Recession path.
• Adjusted operating margin < 0.133 (2 consecutive prints). Margin drives 57 pct of simulated valuation variance. Two prints below 13.3 pct signal reimbursement or wage/supply cost pressure that the Invigorate-style cost programmes are not offsetting.
• Enacted Medicare Clinical Lab Fee Schedule change (annual rate) < -2.0 pct (single event). A PAMA-style fee-schedule cut of 2.0 pct or worse flows almost entirely to operating profit and validates the structural scenario mechanism of earnings and multiple compressing together.
• Revenue per requisition, year on year < -0.015 (2 consecutive prints). Falling unit revenue while volumes hold indicates payer steerage to narrow networks or hospital in-sourcing capturing the mix, the core disintermediation mechanism in the bear path.
• Net debt / EBITDA after announced M&A > 3.25 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $233; 52-week range $171–$249; engine rating SELL; house target $198 (-15%). (source: Alpha Vantage 2026-10-12, 13 October 2026)
• INFERENCE: Triangulated FV $159 (-32% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the DCF anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

50.0/100 (confidence band 36.4–63.7), 19th percentile of 928 covered names (as of 2026-10-12). Weighted composite under config ros-1.21.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 50.8 → 51.2 → 50.7 → 49.8 → 50.1 → 50.1 → 50.1 → 50.2.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $204.21.

Factor Exposures

Cross-sectional percentiles over 928 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.11, vs QQQ -0.01 (trailing ~1y daily returns).

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -14% vs spot
• Monte Carlo median implies -23% vs spot
• DCF fair value (exit-multiple terminal) implies -53% vs spot — but this is terminal-value sensitive (exit-multiple $110 vs Gordon $127, 16% apart), so it carries less weight
• Bear case (Structural — Reimbursement / In-House Testing) downside is -62% vs spot
• Net: the valuation anchor itself sits 31.8% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $5B + PV(terminal) $14B = EV $19B; − net debt $6.6B → equity $12B ÷ diluted shares $0.11B = $110/share (exit-multiple terminal).

• Gordon terminal → $127/share — a single-point perpetual-growth cross-check at g = 2.5% (one growth rate, not a range; it is not in the blend).
• Incremental ROIC on the forecast capex ≈ 7% vs WACC 8.5% → below WACC — the incremental build is value-dilutive.

Peer set

Implied prices at the peer medians: same-sub-industry median fwd P/E → $162; EV/Rev → $61.58.

Weighted fair-value math

Model Calibration Caveats

Raised by the model's own checks on its run of 13 October 2026 (prices as of 2026-10-12). They concern how the model was calibrated, not the company; read the figures they touch with them in mind.

• The Monte Carlo gives only a 29% probability of the price finishing above today's; the house treats readings under 30% as a sign the downside assumptions may be too severe.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Model op margin ±3pp (72.0); Revenue CAGR ±3pp (45.0); Terminal × ±15% (37.0); Capex intensity ±15% (23.0); WACC ±1pp (14.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 15×, FY+5 revenue $13B. Triangulation leans 36% on DCF, 32% on PWEV, 19% on the Monte Carlo median, 13% on peer-implied value.